

Index

Note: Page numbers with the suffix ‘n’ indicate a note, with appropriate number, and ‘t’ a table.

- Abbott Laboratories 118, 187–8, 197–8, 268–9
- Accelerated Access Initiative (AAI) 27, 150–1, 153–6
- Achmat, Zackie 114, 119, 121, 129
see also Treatment Action Campaign
- ACT UP
 - activities 25, 116
 - fragmentation 107–9, 269
 - and the media 13
 - moral framing 13, 65–6
 - support for TAC 114
- ACT UP NYC 107–8, 114
- ACT UP Paris 133
- ACT UP Philadelphia 107–8, 114, 126
- advocacy movements
 - anti-corporate 4
 - and certification standards 7
 - coherence 22, 97–134t, 215–16
 - conceptualization 273
 - contentious vs private politics 5, 8–9, 272–3
 - disruptive tactics 13–14
 - disunity 99–101
 - domestic 9
 - effectiveness 15–18
 - functions 116–17
 - and goods essential for life 71–2, 81–4, 95
 - and human rights 74
 - mobilization of activists 83, 88–9, 91–5
 - non-health-related problems 86–7, 90
 - persuasive tactics 12
 - and political opportunity 10–11
 - principal-agent theory 100
 - radical flank effect 273–4
 - shared meanings 9
 - strategies 5, 22–3
 - success, likelihood of 215–16, 218
 - transnational 2, 8–10, 14–15, 111–12
see also AIDS activism; climate change activism; framing
- Advocacy Network for Africa 113
- AIDS activism
 - achievements 257
 - and ARV drugs 7, 126–31, 139–40
 - civil society actors 113
 - coherence 97, 119–23, 132
 - and corporate donations 24
 - deferral to local activists 129–30
 - divisions and challenges 105–9, 133–4
 - drug access and prices 126–31
 - early tensions 129
 - expertise 39
 - future of 134, 269–71
 - Gaborone conference (2004) 205–6
 - growing unity 130–1
 - historical background 27–9
 - insiders 112–13, 116–17
 - and international conferences 120–2
 - move towards global treatment access 123–6
 - political activity 83, 88–9, 91–5
 - and political opportunity 70
 - pre-convergence 123–6
 - sign-on letters 122–3
 - small core group 130–1
 - structural opportunities for change 11–12, 42–3
 - success of viii, 15–16, 213–14, 264–5
 - support from Northern activists 118–19
 - theory of strategic moral action ix
 - transnational components of 110–19
 - and TRIPS regime 10–11, 43, 51–2, 123
- AIDS/HIV
 - chronic condition in the West 109
 - denialists 108, 117
 - early identification of 25, 275
 - historical background 25–9

Cambridge University Press

978-1-107-03614-7 - AIDS Drugs for All: Social Movements and Market Transformations

Ethan B. Kapstein and Joshua W. Busby

Index

[More information](#)

Index

313

- key dates 29–31
- prevention strategies and divisions 105–7
- public opinion 78–9, 85–6
- scale of epidemic 76–7
- security issue 70
- universality of problem 79–80
- visibility 79–80
- see also* People Living with AIDS (PWAs)
- airline tax *see* UNITAID
- alcohol industry 232, 234
- allergies 85
- Annan, Kofi 112, 177
- antiretroviral (ARV) drugs
 - Accelerated Access Initiative (AAI) 27, 150–1, 153–6
 - advocacy actions 7, 126–31, 139–40
 - combination therapy 26
 - compulsory licensing 128, 146
 - cost per patient 25–6
 - development and evolution 44, 46–9
 - directly observed HAART therapy 141–2
 - Drug Access Initiative (DAI) 142–4, 153
 - effectiveness agreed 144
 - fixed-dose combination (FDC) 205–6
 - funds' market share 176t
 - global implications 126
 - goods essential for life 71–2, 81–4
 - HAART triple cocktail 26, 47–8, 185, 193–4
 - and health infrastructure 136–7
 - long-term prospects 17
 - market stabilization 171–4
 - pooled procurement 184
 - PreP trials 133
 - procurement practices 183–5
 - Protease Inhibitors (PIs) 26, 47–8
 - purchase volumes 189–90
 - Quad 260
 - transferral from private into merit goods 1–2, 170
 - types 47t
 - US waiting lists 110
 - WHO treatment guidelines 191–4
 - see also* generic drugs; names of individual drugs; People Living with AIDS (PWAs); TRIPS regime
- Arrow, Kenneth 224
- Aspen Pharmacare 164, 207–8, 213
- Attaran, Amir 51, 67–8, 189
- Aurobindo 115, 185
- Axelrod, Robert 173
- AZT (zidovudine) 12, 25–6, 44–5, 193, 207
- Balasubramaniam, Thiru 114
- Bale, Harvey 67
- Baron, David P. 38
- Bartley, Tim 7, 14
- Barton, John 53
- Bayer 55–6
- Behrman, Greg 139
- Benn, Christoph 112, 177–8 *see also* *Global Fund*
- Berensky, Adam 81
- Berger, Jonathan 114
- Berkman, Alan 114, 135 *see also* *Health GAP*
- Berman, Daniel 131 *see also* *Médecins sans Frontières (MSF)*
- biotechnology activism 38
- Birmingham, Desmond 237
- bodily harm 9, 21
- Bollyky, Thomas 233–4
- Bolten, Josh 113, 261
- Boneberg, Paul 123–6
- Bonnel, Rene 258
- Bono 113, 132–3, 181
- BP 16
- Brazil
 - AIDS activism 113
 - ARV program 140–1, 143
 - drug purchases 189
 - generic drugs 26, 36, 140
 - Merck dispute 147
 - right to treatment 76, 140–1
 - TRIPS challenge 55
- Breast-Milk Substitutes Code 50, 61–2, 150
- Bristol-Myers Squibb (BMS) 36, 48, 118, 130, 189, 197–8, 268–9
- Brown, Mark Malloch 112
- Brundtland, Gro Harlem 49–50, 112, 121, 152, 177–8
- Burkhalter, Holly 105–6
- Burma, Free Burma Coalition 23
- Burroughs Wellcome 12, 25–6, 36, 44
- Bush, George W.
 - and ARV therapy 140
 - and Clinton 206
 - drug prices 203
 - and Kyoto Protocol 102
 - and PEPFAR 28, 68, 138–9, 179–80
 - Pink Ribbon Red Ribbon 233
- Cameron, Daryl 76–7
- cancer 85–9, 91–4, 233
 - see also* non-communicable diseases
- Cannabrava, Francisco 113
- carbon emissions 22, 101, 239, 241
- carbon markets 18
- carbon tax 16
- certification programs 14
- certification standards 7

Cambridge University Press

978-1-107-03614-7 - AIDS Drugs for All: Social Movements and Market Transformations

Ethan B. Kapstein and Joshua W. Busby

Index

[More information](#)

314 Index

- CHAI *see* Clinton HIV/AIDS Initiative (CHAI)
- children
health 228–30
see also education
- China
greenhouse gases 102
ivory demand 242–5
- Chirac, Jacques 182
- cholera 85–6
- Christy, Bryan 242–3
- Cipla
and AIDS activists 120
and CHAI 157–63
drug delisting 198, 200
and MSF 116
purchase orders 185
reduced price offer (2000) 27–8, 115, 120, 138, 156–7
reduced price offer (2001) 157
tenofovir 188
WHO prequalification drugs 197–8
- Cipro 55–6
- Cleveland, Robin 113
- Climate Action Network (CAN) 98, 102–3
- climate change activism
challenges 241
and climate skeptics 100–1
and costs 240
declining coherence 98
fragmentation 22, 101–3, 240
framing 239–40
and institutions 240
and Kyoto Protocol 37
limited success x, 18
and market transformation 239–41
- Climate Justice Now! 102–3
- Clinton, Bill 14, 27–8, 158, 160, 182, 206
- Clinton HIV/AIDS Initiative (CHAI)/
Clinton Health Access Initiative
achievements 159–60, 165–6
agreements 67–8, 159, 190
and Aspen 164
and business consultancy 160–2
and Cipla 157–63
and drugs market 116
establishment of 28, 157–8
process improvements 166
and Ranbaxy 164
- coherence 22, 97–134t, 215–16
- competition 3
- computers, in education 235–6
- Condliffe, Kate 157–8, 161–2, 165
see also Clinton HIV/AIDS
- contestability 6–7, 10, 32–5, 215–16
- Convention on the International Trade in Endangered Species (CITES) 242–4
- Convention for the Suppression of the Trafficking in Persons 248
- Costa Rica, AIDS activism 118–19
- costs
branded drug company concerns 144
challenging factor 215–16
clean water 231
and climate change activism 240
generic drug company concerns 145
government concerns 137–44
implementation costs 138
malaria interventions 223
and market transformation 22–3, 135–6
maternal mortality 228
reputational costs of inaction 13–14, 32, 69, 145
of slave trade abolition 251–2
- Côte d'Ivoire 143
- CPTech 66–7, 114, 116, 120–1
- d4T (stavudine) 192–4
- Danzon, Patricia M. 46, 149
- Daschle, Tom 204
- DATA 113, 132
- Daulaire, Nils 115
- Davis, Paul 114, 119–20 *see also* *Health GAP*
- ddI (didanosine) 118
- deaths
AIDS 76
by health problem 76
declining rates of 126
likelihood 85, 89, 92–3
PWAs without treatment 65–7
- Debt2Health 181n6
- diarrheal diseases
challenges for market transformation 18
and clean water 229–31
framing 230
funding for 214
public perception of 79, 85–6, 89, 92
- didanosine (ddI) 118
- Doctors without Borders *see* MSF (*Médecins sans Frontières*)
- Donnelly, John 179–80
- donors 17, 258
- Doust-Blazy, Philippe 182
see also UNITAID
- Drahos, Peter 188
- Drezner, Daniel 70
- Druckman, James 60
- Drug Access Initiative (DAI) 142–4, 153

Cambridge University Press

978-1-107-03614-7 - AIDS Drugs for All: Social Movements and Market Transformations

Ethan B. Kapstein and Joshua W. Busby

Index

[More information](#)

Index

315

- drug prices
 - Accelerated Access Initiative 153–4
 - AZT 44–5
 - CHAI achievements 159–60
 - and deaths without treatment 65–7
 - differential pricing 12, 43, 148–56, 265–8
 - early activism 124–5
 - economic problem 45–6
 - effect of pooled procurement 211
 - and expanded access 138–9
 - government concerns 137–8
 - information on 116
 - lowered in exchange for intellectual property 143, 145
 - parallel imports 265
 - PEPFAR 208–10
 - and profit margins 166, 174
 - profit-maximizing 46
 - reference pricing 265
 - and research and development 45, 57, 149
 - strategy convergence 127–8
 - treatment costs 153
 - users shielded from real costs 38–9
 - vs inadequate health infrastructure 136–7
- drugs
 - access to essential medicines 49–51
 - hypertension drug survey 82–4
 - for malaria 221–2, 224–6
 - for non-communicable diseases 232–3
 - praziquantel 50–1
 - sexual impotence drug survey 82–4
 - tariffs 271
 - see also* antiretroviral (ARV) drugs; generic drugs
- Dybul, Mark *see also* PEPFAR
 - and drug quality 205–7
 - funding diversity 258, 263
 - Global Fund director 263–4
 - inside activist 113, 116–17, 179
 - and PEPFAR 179–80, 261
- economic opportunity 11
 - see also* market transformation
- eczema survey 85
- Eddy, R.P. 112
- Edson, Gary 113
- education
 - access to 36, 86–7, 90, 92
 - funding for 213–14, 237–8
 - institutions 238
 - and journal access 236
 - laptops and software 235–6
 - market transformation 235–8
 - primary schools 235, 237
 - universities 236–7
- Eigo, Jim 32
- elephant ivory trade 241–5
- emissions trading scheme 102
- employment, access to 86–7, 90
- Empower America 113–14
- emtricitabine (FTC) 193
- energy sector 16, 239
 - see also* climate change activism
- environmental activism 12
 - see also* climate change activism; ivory trade
- equality of opportunity 62
- Essential Medicines List (WHO) 49, 51
- European Union, emissions trading scheme 102
- Every Mother Every Child 230
- Every Woman and Every Child 228–9
- Family Research Council 113–14
- Fan, Victoria 261
- Farmer, Paul 115, 141–2, 180, 263
- Fauci, Anthony 113, 179, 204
- Feachem, Richard 112, 116–17, 177, 182–4, 223, 260 *see also* Global Fund
- Fink, Sheri 232, 234
- Finnemore, Martha 21, 62
- Fire in the Blood* (documentary) 75–6, 139
- firms
 - certification programs 14
 - conditions for market transformation ix
 - contestability 32–3
 - and corporate social responsibility ix, 163, 272–3
 - donation schemes 24
 - and institutional stability 172
 - multinational 2, 4, 9–10, 64–5, 167
 - and private politics 5, 8–9
 - reputations 13–14, 32, 69, 145
 - stock prices 13
 - see also* pharmaceutical industry
- Fligstein, Neil 5–6, 10, 24, 172
- fluconazole 153
- fluidity of rules 20–1, 34, 36–7, 52
- Focus on the Family 106
- food, access to 86–7, 90, 92
- Food and Drug Administration (FDA) 206–9
- framing
 - AIDS campaign examples 65–9
 - bodily harm norm 21, 61–2
 - climate change 239–40
 - compelling frames 61–5
 - definition 59
 - diarrheal disease 230
 - education 237
 - and equality of opportunity 62

Cambridge University Press

978-1-107-03614-7 - AIDS Drugs for All: Social Movements and Market Transformations

Ethan B. Kapstein and Joshua W. Busby

Index

[More information](#)

316 Index

- framing (cont.)
 goods necessary for life 58–9, 71–2
 human rights 72–6
 importance of 59–61, 215–16
 local cultural context 63
 malaria 222–3
 maternal mortality 227
 moral justice 13–14, 70–81
 safe motherhood 103–4
 slave trade 251
 universal appeal 62–5
 France, political opportunity for change 11
 Frechette, Louise 112, 178
 Frenk, Julio 258, 263
 Frist, Bill 113, 179
 FTC (emtricitabine) 193
 funding
 alternative sources 180–1
 challenges 262
 future uncertainty of 211–12, 257–9
 for generics 28
 multilateral 170
 and public opinion 80
see also donors
- Galambos, Louis 42
 Gangte, Loon 117–18
 Garnier, Jean-Paul 12, 33
 Garrett, Laurie 105, 140, 257
 Gartner, David 213–14
 Gates, Bill 223
 Geffen, Nathan 114, 133
see also *Treatment Action Campaign*
 generic drug manufacturers
 and branded companies 156
 business consultancy 160–2
 concerns 145
 Hatch-Waxman Act (1984) 40
 and intellectual property 162, 167–8
 openings for 42–3
 quality 156
 generic drugs
 and AIDS activism 23, 123, 156–66
 Brazil 113
 development of 115
 duplication of testing procedures 207–8
 India 90, 115, 187–8, 190
 market share 191t
 PEPFAR purchases t209–10
 purchase volumes 189–90
 treatment in developing world 48
 US testing procedure 203–10
 voluntary licensing 186, 188–9, 260
 WHO prequalification scheme t194–201
see also TRIPS regime
- Gerson, Michael 113, 138–9, 179
 Gettleman, Jeffrey 242
 Gilead 48, 133, 187–8, 200–1,
 260, 270
 Gillespie-White, L. 67–8, 189
 Gilmartin, Raymond 151–2 *see also* *Merck*
 Glaxo Wellcome 152–3
 GlaxoSmithKline (GSK) 12, 33, 48,
 197–8, 266
 Global AIDS Action Network (GAAN)
 124, 132
 Global AIDS Alliance 106, 113, 122, 132
 Global AIDS Roundtable 113
 Global Business Coalition against AIDS 111
 global economy, and transnational
 advocacy 2
 Global Fund to Fight AIDS, Tuberculosis
 and Malaria
 Affordable Medicines Facility for Malaria
 (AMFm) 224–6
 ARV market share 184t
 creation of 28, 112, 175–9n4
 disbursements 175
 independent agency 176–8
 management and finance problems 29,
 132, 175, 263–4
 procurement practices 183–5
 Global Health Council 113, 132
 global justice movement 22
 Gonsalves, Gregg
 and ACT UP Paris 133
 and AIDS activism 1, 117, 119
 and compulsory licensing 128
 concerns 132–4
 and sign-on letters 122
 Goosby, Eric 115
 Gore, Al 101–2, 128–9, 146
 Gostin, Lawrence 73–5
 Gould, Deborah B. 109
 Govindaraj, Ramesh 50–1
 Grebe, Eduard 97–8, 114–15
 greenhouse gases 101n2, 239, 241
 Greenpeace 8, 16
 Grepin, Karen 105
 Grubb, Ian 143–4
 guinea worm 85–6
- HAART therapy 26, 47–8
 Haddad, Bill 120–1, 161, 196, 204
see also *Cipla*
 Hadden, Jennifer 98, 102–3
 Haiti
 directly observed therapy 141–3
 Partners in Health 26
 Halperin, Daniel 261

Cambridge University Press

978-1-107-03614-7 - AIDS Drugs for All: Social Movements and Market Transformations

Ethan B. Kapstein and Joshua W. Busby

Index

[More information](#)

Index

317

- Hamied, Yusuf 115, 120, 156–7, 161, 196
see also Cipla
- Harrington, Mark 108, 119
- Hawkins, Darren G. 73–4
- health
 advocacy challenges 233–5
 Alma-Ata Declaration 264–5
 complex vertical disease interventions 262–3
 and death likelihood 85, 89, 92–3
 death statistics 93
 funding disparities 214
 global health 173n2
 non-communicable diseases (NCDs) 232–5
 and obesity 77
 personal responsibility for 86, 92
 public opinion *see* public opinion
 treatment as human right 86, 90, 92
 vaccines 233
see also cancer; diarrheal diseases; hypertension
- Health Action International (HAI) 120–1
- Health for All 75
- Health GAP
 actions 123
 communications 122, 132
 origins 27, 147
 strategy 116, 148
- Health and Human Rights* (journal) 73
- health service
 access to 86, 90, 92
 infrastructure 136–7, 139
 research investment 7–8
- Helms, Jesse 77–8
- Hetero 115
- Heywood, Mark 114
- HIV/AIDS *see* AIDS/HIV; People Living with AIDS (PWAs)
- Holbrooke, Richard 111, 206
- homosexuality 77–8
- housing, access to 86–7, 90, 92
- How to Survive a Plague* (film) 109
- human rights *see* rights
- human trafficking *see* sex trafficking
- hypertension 82–9, 91–4
- I-MAK (Initiative for Medicines, Access & Knowledge) 133, 270
- impotence 82–5, 87–9, 91–4
- India
 advocacy groups 117–18
 d4T phasing out 193–4
 generic drugs 90, 115, 187–8, 190
 greenhouse gases 102
 health opinion survey 90–2, 95
 patents challenges 267–9
 second-line drugs and generic versions 211
see also Cipla
- industry opportunity 11
see also market transformation
- infrastructure, access barrier 67
- institutions
 and climate change 240
 durability of 17–18, 24, 274–5
 education 238
 factor for success 215–16
 life cycle 256
 market stabilization 172–4
 women and children's health 228–9
- insurance schemes 38–9, 45
- intellectual property
 academic journals 236
 advocacy challenges 167
 fluidity of rules 34
 and generic drug companies 162, 167–8
 guarantees, for lower prices 143, 145
 and product development 24, 52
 variable regimes 52–3 *see also* TRIPS regime
- International Conference of Harmonisation (ICH) 90, 197n20
- International Monetary Fund (IMF) 62
- international organizations 64, 111–12, 170–1
- International Treatment Preparedness Coalition (ITPC) 114, 117–18
- internet 122
- ivory trade 241–5
- James, John S. 119–20
- Japan
 AIDS funding 80
 ivory demand 243
- Johnson, Krista 75
- journal access 236
- Juneja, Sandeep 163–4
- Kaletra 118, 187–8, 268–9
- Kantor, Mickey 267
- Kaplan, Karyn 119
- Kaufmann, Chaim D. 250–2
- Keck, Margaret E. 9, 21, 58, 61–3, 74, 99
- Kennedy, Edward 204–5
- Kenya, d4T phasing out 193–4
- Keohane, Robert 172–3
- Kim, Jim 68–9, 112, 121
- King, Brayden G. 10, 12–13, 41–2
- Knowledge Ecology International (KEI) 133
- Kolbe, Jim 106

Cambridge University Press

978-1-107-03614-7 - AIDS Drugs for All: Social Movements and Market Transformations

Ethan B. Kapstein and Joshua W. Busby

Index

[More information](#)

318 Index

- Kramer, Larry 13, 107–8
 Krauss, Kate 124, 126–7
 Kyoto Protocol 101–2
- La Mure, Lane T. 23
 Langdon, David 120
 Lange, John 206
 laptops 235–6
 Lederer, Bob 119–20
 Lee, Jong-Wook 112, 182
 Lee, Taeku 77
 Lefkowitz, Jay 113, 179
 Legro, Jeffrey W. 100
 Lieberman, Evan S. 73
 Love, Jamie
 activities 119–20, 130
 ARV patents 189
 and Cipla 120
 and CPTech 114, 116
 and drug prices 139
 and Gilead 270
 KEI 133
 strategy 66–7, 71–2, 135, 148
 US activism 147
 Lucchini, Stéphane 189–90
- McAlpin, Loring 119
 McCain, John 204–5
 Magaziner, Ira 157–8, 160–2, 165, 182, 206
 see also Clinton HIV/AIDS Initiative
- malaria
 activists' divisions 223
 AMFm 224–6
 bed nets 221, 223
 framing 222–3
 funding 223–4
 Malaria No More 218, 222–3
 market transformation 218–27
 public opinion 85–6, 89–90, 92
 Roll Back Malaria 221
 strategy challenges 226–7
 treatment drugs 221–2, 224–6
- Mandela, Nelson 146
 Mann, Jonathan 72–3, 139–40
- market transformation
 advocacy strategy 5, 253–4
 ARV access regime 171–4
 clean water 229–31
 and climate change 239–41
 cost–benefit strategies 22–3, 135–6
 economic/industry opportunity 11
 education 235–8
 likelihood hypotheses 20–1
 malaria 218–27
 maternal health 227–9
 objectives 4–5
 political opportunity 10–11
 sex trafficking 245–50
 slave trade 250–2
- markets
 and budgetary constraints 4
 and competition 3
 contestability 6–7, 10, 32–5, 215–16
 definition 3
 fluidity of rules 20–1, 36–7, 52
 market concentration 20, 35–6
 and monopolies 6
- Martin, Jerome 133
- maternal mortality
 framing 227
 funding 104
 institutions 228–9
 market transformation 227–9
 Millennium Development Goals (MDGs) 103, 229
 and movement coherence 103–4
- Matrix 158–9, 200–1
- Maxmen, Amy 226
- Mbeki, Thabo 117
- media 13
- medicines *see* drugs
- Medicines Patent Pool (MPP) 133–4, 268–70
- Merck 67, 118, 147, 152–3
- Milano, Mark 96, 100, 127–30 *see also ACT UP*
- Millennium Development Goals 103, 229–31, 235
- monopolies 6
- morality 13–14, 65–6, 68, 70–81
- MSF (Médecins sans Frontières)
 Access Campaign 49–50, 120–1, 131
 consensus creation 127
 function 116
 pilot projects 142
 press releases 58, 66
- Mugenyi, Peter 115, 180
- Mukherjee, Siddhartha 17
- multinational firms 2, 4, 9–10, 64–5, 167
- Natsios, Andrew 67
- Navarro, David 178
- Nestlé 50, 61–2, 150
- Netherlands, sex workers 247
- NGOs, professionalism 99
- Nicolaou, Stavros 164
- Nigeria, drug purchases 189–90
- NNRTIs (Non-Nucleoside Reverse Transcriptase Inhibitors) 47–8, 193

Cambridge University Press

978-1-107-03614-7 - AIDS Drugs for All: Social Movements and Market Transformations

Ethan B. Kapstein and Joshua W. Busby

Index

[More information](#)

Index

319

- non-communicable diseases (NCDs) 232–5
- non-governmental organisations, professionalism 99
- norms 9, 21
- North, Douglass 172
- NRTIs (Nucleoside Reverse Transcriptase Inhibitors) 47–8, 193
- obesity 77, 85–6
- Occupy Wall Street 22, 255
- Odell, John S. 65
- oil industry 16
- Oliver, J. Eric 77
- ONE Campaign 113, 132–3
- Orbinski, James 50
- Over, Mead 107, 258–9
- Oxfam 8, 33, 42
- Pape, Jean William 115
- Pape, Robert A. 250–2
- Pappas, Gregg 119–20
- patents 40, 67–8, 189
 - Indian challenges 267–9
 - see also* intellectual property; TRIPS regime
- Payne, Keith 76–7
- Payne, Roger A. 63
- Pearce, Nicholas 10, 12
- Pécoul, Bernard 114, 120, 122, 127, 131, 142 *see also* *Médecins sans Frontières*
- People Living with AIDS (PWAs)
 - adherence to treatment 260
 - advocacy role 117
 - and bodily harm 9, 21
 - cultural barriers 67
 - deaths 76–7
 - deaths without treatment 65–7
 - discrimination 72
 - fairness for drugs access 59–60
 - Global Network (GNP+) 121
 - and human rights 72–6
 - loss to follow-up 259
 - personal responsibility for the disease 77–9, 86
 - public knowledge of 79–80
 - treatment challenges 260–2
 - treatment numbers 17, 28–9, 134, 150, 157, 189–90
 - treatment regime 48–9
- PEPFAR
 - ARV market share 184t
 - budget 176t
 - creation of 28, 115, 138–9, 179–80
 - disbursements 107, 175–6
 - drug prices 208–10
 - drug purchases 209–10t
 - goal 203, 208
 - and morality 68
 - procurement practices 183–5
 - treatments 261
- Perez-Casas, Carmen 112, 208
- Perriens, Joseph 143, 151–2 *see also* *Drug Access Initiative and Accelerated Access Initiative*
- persuasive tactics 12
- Pfizer 48, 153
- pharmaceutical industry
 - challenge for advocacy movements 32, 38–9
 - contestability 32–5
 - globalization 42
 - market concentration 36, 39, 211
 - Medicines Patent Pool (MPP) 133–4, 268–70
 - mergers and acquisitions 12, 41–2
 - regulation 39–40
 - reputation 13–14, 32, 69
 - South African lawsuit 54–5, 66–7, 128–9, 146–7
 - transnational ties 65n4
 - see also* drug prices; generic drugs; intellectual property; patents; TRIPS regime
- Pinheiro, Eloano 113
- Pink Ribbon Red Ribbon 233
- Piot, Peter *see also* *UNAIDS*
 - AIDS activism 73, 114, 140
 - and AIDS prevention 106–7
 - and differential pricing 151–2, 154–5
 - Drug Access Initiative 142, 144
 - and drug pricing 128, 150
 - early difficulties 124
 - funding diversity 258, 263
 - and Global Fund 178–9
 - inside role 111–12, 116–17
 - and Sawyer 121, 124
- Plumley, Ben 153
- Pogge, Thomas 75
- political activity 83, 88–9, 91–5
- political opportunity 10–11, 70
- politics, contentious vs private politics 5, 8–9, 272–3
- Porter, Michael 34
- Prakash, Aseem 69–70
- praziquantel 50–1
- primary schools 235, 237
- principal-agent theory 99–100
- Product RED 181
- prostitution 247
- Protease Inhibitors (PIs) 26, 47–8

Cambridge University Press

978-1-107-03614-7 - AIDS Drugs for All: Social Movements and Market Transformations

Ethan B. Kapstein and Joshua W. Busby

Index

[More information](#)

320 Index

public opinion

- AIDS funding 80
- cancer 85–9, 91–4
- diseases 84–95
- high cholesterol 85–6
- HIV and goods essential for life 81–4
- HIV/AIDS and other diseases 79, 85–6
- hypertension 82–9, 91–4
- Indian survey 90–2
- and individual behavior 78
- persuasive messages 100
- sexual impotence 82–5, 87–9, 91–4
- surveys 80–95
- third world diseases 79
- US surveys 87–90, 93–5

Rabinowitz, Rebecca 232, 234

Rago, Lembit 112

Rainforest Action Network 33

Ranbaxy 48, 115, 163–4, 198, 209

Rawls, John 4

Reich, Michael 50–1

research, ideas for 256, 271–5

RESULTS Alliance 113, 237

rhinos 241–2

Rice, Condoleezza 113, 179

Richard, Bill 120

rights 72–6, 86, 90, 140–1, 246

see also framing

Riley, John 119–20

Ripin, David 165–6

Risse, Thomas 74

Rodrik, Dani 5

Roemer-Mahler, Anne 169, 194–5

Roosevelt, Franklin D. vii

rules, fluidity of 20–1, 34, 36–7, 52

Russell, Asia 114, 119–21, 126

see also *Health GAP*

Rustin, Bayard 273

Saba, Joseph 143

Sachs, Jeffrey 115

Saddleback Church 106

Samaritan's Purse 113–14

Samb, Badara 142–3

Sawyer, Eric *see also* *ACT UP and Health GAP*

activities 120–1, 130

and Al Gore 129

on drugs companies 65–6

early difficulties 124–5

and global treatment access 124–5, 127, 139

insider role 112

Love's strategy 148

and Piot 121, 124

schistosomiasis 50–1

Schurman, Rachel 38

Schwartländer, Bernhard 150, 155

Sell, Susan 65, 69–70

Serra, José 113

sex trafficking

advocacy movements 14–15, 246–8, 250

Dutch legalization 247

government involvement 248

incidence of 245, 249

market transformation 245–50

methods 245–6

Swedish prostitution law 247–8

US action 248–9

sexual impotence 82–5, 87–9, 91–4

Shadlen, Kenneth C. 211

shareholder activism 12–13, 15, 42

shelter, access to 86–7, 90, 92

Shiffman, Jeremy 103–4, 214, 227–9

Sikkink, Kathryn 9, 21, 58, 61–3, 74, 99

Silverman, Rachel 261

Siplon, Patricia A. 108

Slaughter, Anne-Marie 111–12

slave trade 14–15, 216, 246, 250–2

see also sex trafficking

Smith, Craig 16

Smith, Raymond A. 108

Smith, Stephanie 103–4, 227–9

social movements *see* advocacy movements;

AIDS activism; climate change

activism

software 235–6

Soule, Sarah A. 13

South Africa

compulsory licensing 128

AIDS activism 114–15, 119, 123

Aspen Pharmacare 164, 207–8, 213

compulsory licensing 146

drug imports 129

drug industry lawsuit 11, 27, 54–5, 66–7, 128–9, 146–7

HIV/AIDS spending 262

human rights 76

Treatment Action Campaign (TAC) 27, 114–15, 117, 119

US sanctions threat 69, 146

Spar, Debora L. 23

Spitzer, Eliot 255

state failure 70

stavudine (d4T) 192–3

Stern, Richard 118–19

Sturchio, Jeff 150, 152, 154 *see also* *Merck*

Suwannawong, Paisan 119

Cambridge University Press

978-1-107-03614-7 - AIDS Drugs for All: Social Movements and Market Transformations

Ethan B. Kapstein and Joshua W. Busby

Index

[More information](#)

Index

321

- Sweden, prostitution 247–8
 Sykes, Richard 152–3
- 't Hoen, Ellen 112, 114, 122, 133, 154, 187, 269–70 *see also Médecins sans Frontières and Medicines Patent Pool*
 tariffs 271
 Tarrow, Sidney 8, 22
 Teixeira, Paolo 113
 tenofovir (TDF) 166, 187–8, 193, 200–1
 Thailand
 AIDS activism 118–19
 generic drugs 36
 ivory trade 242–3
 Thompson, Tommy 55–6, 204
 Thrupkaew, Noy 247–8
 Timberg, Craig 261
 tobacco industry 232, 234–5
 Tobias, Randall 204–5
 transnational advocacy 2, 8–10, 14–15, 111–12
 see also advocacy movements
 Treatment Action Campaign (TAC) 27, 114–15, 117, 119
 Treatment Action Group (TAG) 108
 TRIPS regime
 and AIDS activism 10–11, 43, 51–2, 123
 ambiguity of interpretation 37
 challenges to 54–6
 and compulsory licensing 128, 146, 186–7
 Doha Declaration (2001) 56, 63–4, 113, 186–7
 flexibilities (health exception) 28, 54, 186–7
 and high price of AIDS drugs 26
 negotiations 53
 paragraph 6 solution (2003) 186–8
 South Africa challenge 11, 27, 54–5, 146–7
 terms 53–4, 186
 TRIPS-plus 266–7
 tuberculosis 79, 85–6, 89–90
- Uganda, AIDS program 180
 UNAIDS
 Accelerated Access Initiative (AAI) 27, 150–1, 153–6
 creation 26
 Drug Access Initiative (DAI) 142–4, 153
 and Global Fund 178
 and global treatment access 140
 Piot's tenure 106–7, 121, 140
 Treatment 2.0 program 259
- UNITAID
 ARV market share 184t
 and CHAI 159
 creation 28, 181–2
 disbursements 181
 Medicines Patent Pool (MPP) 133–4, 268–70
 procurement practice 184–5
 strategy 261
 United Nations
 bureaucracy 177–8
 Every Woman and Every Child 228–9
 General Assembly 28, 112
 non-communicable diseases 232
 Security Council 27, 111
 and sex trafficking 248
 United States
 AIDS advocacy 9, 106, 113, 119–20
 AIDS advocacy divisions 105–9
 ARV waiting lists 110
 Bayer's anthrax patent 55–6
 Brazil's Merck dispute 147
 drug prices 208–10
 Focus on the Family 106
 Food and Drug Administration (FDA) 206–9
 and generic drug testing 203–10
 health care 14
 HIV incidence in black community 110
 Kyoto Protocol 101–2
 Occupy Wall Street 22, 255
 opinion surveys 87–90, 93–5
 political opportunity for change 10–11
 and sex trafficking 248–9
 South African sanctions threat 54–5, 69, 128–9, 146
 and Treatment Action Group (TAG) 108
 TRIPS challenges 54–5
 TRIPS-plus agreements 266–7
 and WHO prequalification scheme 203, 205–7
 see also ACT UP; Clinton HIV/AIDS Initiative (CHAI); Health GAP; PEPFAR
 universities 236–7
- vaccines 233
 Van Zyl, Andre 112, 200
 Victor, David G. 241
 Vietnam, UNAIDS pilot trial 143
- Waning, Brenda 160, 174, 193
 Warren, Rick 106
 water
 access to 86–7, 90, 92

322 Index

- water (cont.)
 - clean water costs 231
 - market transformation 229–31
- Waxman, Henry 205, 209
- Weg, Ken 151–2
- Weissman, Rob 120
- WHO
 - 3 by 5 initiative 68–9
 - Breast-Milk Substitutes Code 50
 - drug delisting 198, 200
 - Essential Medicines List 49, 51
 - Global Price reports 190
 - prequalification scheme 194–201t
 - rivalries with UNAIDS 155
 - treatment guidelines 191–4
 - US and prequalification scheme 203, 205–7
 - see also* Accelerated Access Initiative (AAI);
Drug Access Initiative (DAI)
- Williamson, Oliver 1
- women 74, 229–30
 - see also* maternal mortality
- Wong, Wendy 130–1
- World Bank 62, 237
- World Economic Forum 121
- World Trade Organization (WTO)
 - 9–10, 27
 - see also* TRIPS regime
- Youde, Jeremy 75, 264–5
- Zaller, John 100
- Zeitz, Paul 106
- zidovudine (AZT) 12, 25–6, 44–5, 193, 207
- Zimbabwe, d4T phasing out
 - 193–4
- Zuma, Jacob 262